Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 30, 2025, to announce its financial results for the third quarter of 2025. The filing primarily includes a press release detailing these results and a presentation covering financial and operating initiatives discussed during the company's conference call. Investors should review these furnished documents for a comprehensive understanding of BMY's performance and strategic direction. The company has made available both the Earnings Press Release and the Bristol Myers Presentation on its website. These materials contain forward-looking information, including references to non-GAAP financial measures. BMY has also provided reconciliations for these non-GAAP figures to their comparable GAAP counterparts, which are crucial for investors seeking to interpret the financial performance accurately. It is important to note that this information is furnished and not considered "filed" under the Securities Exchange Act, meaning it does not carry the same liability implications as formally filed documents, but it is still material for investment decisions.
Key Highlights
- 1BMY announced its third quarter 2025 financial results on October 30, 2025, via an 8-K filing.
- 2The filing includes an Earnings Press Release (Exhibit 99.1) detailing financial performance.
- 3A Bristol Myers Presentation (Exhibit 99.2) on financial and operating initiatives is also provided.
- 4Both documents are available on the company's website and incorporated by reference into the 8-K.
- 5The company references non-GAAP financial information in its disclosures.
- 6Reconciliations between non-GAAP and GAAP financial measures are available in the Earnings Press Release.
- 7The furnished information is not deemed 'filed' for purposes of Section 18 of the Exchange Act.